Altitude Sickness

Altitude sickness encompasses conditions such as acute mountain sickness (AMS), high-altitude pulmonary edema (HAPE), and high-altitude cerebral edema (HACE), affecting individuals ascending to high altitudes without proper acclimatization. The fundamental cause is decreased barometric pressure, leading to reduced oxygen availability. Acclimatization is the body’s adaptive response, involving respiratory, cardiovascular, pulmonary, hematopoietic, and cerebral circulatory adjustments. Key factors influencing acclimatization include the rate of ascent, altitude, individual susceptibility, and physical fitness. 

AMS, the most common altitude illness, typically occurs above 2500 meters. Symptoms include headache, anorexia, nausea, fatigue, and lightheadedness. Diagnosis relies on reported symptoms. Prevention involves gradual ascent, limiting sleeping elevation gains, and prophylactic medications. Treatment includes descent, oxygen, acetazolamide, or dexamethasone. 

HAPE is a potentially fatal condition with fluid leakage into the alveoli. Symptoms include dyspnea at rest, dry cough, and cyanosis. Diagnosis involves clinical assessment and pulse oximetry. Prevention includes gradual ascent and nifedipine for those with a history. Treatment requires immediate descent and oxygen therapy. 

HACE, the most severe form, is progression from AMS, characterized by ataxia, severe headache, nausea, vomiting, and altered mental status. Diagnosis is based on clinical assessment. Treatment prioritizes rapid descent, high-flow oxygen, and dexamethasone. 

Chronic mountain sickness (CMS) affects long-term high-altitude residents, marked by excessive erythrocytosis. Treatment involves descent, oxygen therapy, and medications like acetazolamide. 

Awareness, effective prevention strategies, and prompt treatment are crucial to mitigate life-threatening complications associated with altitude sickness.